Bortezomib in the treatment of multiple myeloma

Multiple Myeloma (MM) is the second most-common blood cancer, resulting from overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer-drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon suppression of pro-apoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from oncology and pharmacology, working either in academia or the pharmaceutical industry.

• ISBN: 978-3-7643-8947-5
• Editorial: Birkhaüser
• Encuadernacion: Cartoné
• Páginas: 250
• Fecha Publicación: 01/06/2010
• Nº Volúmenes: 1
• Idioma: Inglés